Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic NeuritisGlobeNewsWire · 3 days ago
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic NeuritisGlobeNewsWire · 3 days ago
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS MeetingGlobeNewsWire · 5 days ago
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS MeetingGlobe News Wire · 5 days ago
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrkiGlobeNewsWire · 6 days ago
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye DiseaseGlobeNewsWire · 6 days agoOculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.48 | -$0.20 | Beat |
| May 11, 2026 | -$0.49 | -$0.63 | Miss |
| Mar 3, 2026 | -$0.48 | -$0.51 | Miss |
| Nov 10, 2025 | -$0.50 | -$0.40 | Beat |
| Aug 21, 2025 | -$0.53 | -$0.59 | Miss |
| May 8, 2025 | -$0.51 | -$0.77 | Miss |